BridgeBio Oncology Therapeutics, Inc.
BBOTNext catalyst
BBP-418
Get an email about BBOT's next catalysts
Track BridgeBio Oncology Therapeutics (BBOT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, data readout).See the timeline
3 upcoming, 0 past
BBOT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.65 | FQ end Sep/2026 | Call: tbd
FDA PDUFA Date BBP-418
AI-extracted from news: BridgeBio signals 3 launches in next 7 months with BBP-418 November 27 PDUFA and infigratinib Februa
SourceData Readout
BridgeBio Oncology Therapeutics has a KRAS program with data expected in the second half of 2026, which may generate positive sentiment among investors.
SourceMarket Overview
Stock performance and key metrics
Acoramidis (AG10)
Amyloid Cardiomyopathy, Transthyretin-Related
Infigratinib
Achondroplasia
Encaleret
Autosomal Dominant Hypocalcemia (ADH)
acoramidis
Amyloidosis
BBT-207
EGFR Mutant Advanced Non-Small Cell Lung Cancer
PTR-01
Recessive Dystrophic Epidermolysis Bullosa
Infigratinib is provided as sprinkle capsules for daily oral administration
Achondroplasia
Infigratinib is provided as a single dose of minitablets for oral administration
Achondroplasia
AG10
Amyloid Cardiomyopathy
BBT-877
Idiopathic Pulmonary Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acoramidis (AG10) | Phase 3 | Amyloid Cardiomyopathy, Transthyretin-Related | - | - |
Infigratinib | Phase 3 | Achondroplasia | - | - |
Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) | - | - |
acoramidis | Phase 3 | Amyloidosis | - | - |
BBT-207 | Phase 2 | EGFR Mutant Advanced Non-Small Cell Lung Cancer | - | - |
PTR-01 | Phase 2 | Recessive Dystrophic Epidermolysis Bullosa | - | - |
Infigratinib is provided as sprinkle capsules for daily oral administration | Phase 2 | Achondroplasia | - | - |
Infigratinib is provided as a single dose of minitablets for oral administration | Phase 2 | Achondroplasia | - | - |
AG10 | Phase 2 | Amyloid Cardiomyopathy | - | - |
BBT-877 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Frequently asked questions
What is in BridgeBio Oncology Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in BridgeBio Oncology Therapeutics, Inc.'s (BBOT) pipeline across Phase 3, Phase 2. Its lead program is acoramidis (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BridgeBio Oncology Therapeutics, Inc.'s next FDA catalyst?→
BridgeBio Oncology Therapeutics, Inc.'s (BBOT) next tracked catalyst is a PDUFA date expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BBOT biotech catalysts?→
Add BBOT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BridgeBio Oncology Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.